본문으로 건너뛰기
← 뒤로

Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments.

Seminars in cancer biology 2025 Vol.116() p. 108-120

Li J, Chen L, Liu X, Zhang M, Liu X

📝 환자 설명용 한 줄

Immune checkpoint inhibitors (ICIs) enhance systemic antitumor immune responses by improving the ability of immune cells to recognize and kill tumor cells specifically.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Li J, Chen L, et al. (2025). Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments.. Seminars in cancer biology, 116, 108-120. https://doi.org/10.1016/j.semcancer.2025.09.006
MLA Li J, et al.. "Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments.." Seminars in cancer biology, vol. 116, 2025, pp. 108-120.
PMID 40998098

Abstract

Immune checkpoint inhibitors (ICIs) enhance systemic antitumor immune responses by improving the ability of immune cells to recognize and kill tumor cells specifically. Activated T lymphocytes may target tissues and organs outside the tumor, leading to different degrees of immune-related adverse events (irAEs). Immune checkpoint inhibitor-associated myocarditis (ICIAM) is a rare irAE, with an incidence of approximately 0.04-1.7 %. However, it is the most fatal irAE and often becomes a critical cause of short-term mortality in patients. Currently, the molecular mechanisms of ICIAM involve immune damage mediated by T-cell and macrophage infiltration, the common antigen theory, and pro-inflammatory responses driven by inflammatory factors and signaling pathways. However, the specific mechanisms remain unclear. A comprehensive understanding of the pathophysiological mechanisms of ICIAM can aid in identifying biomarkers and treatment targets for irAEs, ultimately improving the survival status of patients with cancer.

MeSH Terms

Humans; Immune Checkpoint Inhibitors; Myocarditis; Neoplasms; Animals

같은 제1저자의 인용 많은 논문 (5)